跳至主要内容
临床试验/NCT02616861
NCT02616861已完成1 期

A 2-stage Phase 1 Study of Safety, Tolerability, PK, and PD of IW-1973 Tablet in Healthy Volunteers in an Open-label, Single-dose Stage, and a Randomized, Double Blind, Placebo-controlled, Multiple-ascending-dose Stage

Cyclerion Therapeutics1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2015年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
54
试验地点
1
主要终点
Treatment Emergent Adverse Events

研究概览

简要总结

Stage 1: To assess the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of the IW-1973 Tablet administered orally to healthy volunteers, in fed and fasted states, in a single-dose crossover study.

Stage 2: To assess the safety, tolerability, PK profile, and PD effects of a range of doses of IW-1973 Tablet administered orally to healthy subjects in a 21-day, multiple ascending-dose study with optional up-titration of dose level within cohort.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is an ambulatory male or female between 18 and 55 years old at the Screening Visit
  • Subject's body mass index score is > 18.5 and < 30.0 kg/m2 at the Screening Visit
  • Women of childbearing potential must have a negative pregnancy test and must agree to use double-barrier contraception
  • Subject is in good health and has no clinically significant findings on a physical examination
  • Other inclusion criteria per protocol

排除标准

  • History of any clinically significant medical condition
  • Other exclusion criteria per protocol

研究组 & 干预措施

IW-1973

Experimental

1973 Escalating Doses

干预措施: IW-1973 (Drug)

Placebo

Placebo Comparator

Matching Placebo

干预措施: Matching Placebo Tablet (Drug)

结局指标

主要结局

Treatment Emergent Adverse Events

时间窗: 42 Days

Maximum observed plasma concentration (Cmax)

时间窗: 42 Days

Serum cGMP

时间窗: 42 Days

Blood Pressure

时间窗: 42 days

Area under the plasma concentration time curve during a dosing interval (AUC)

时间窗: 42 Days

Time of maximum observed plasma concentration (Tmax)

时间窗: 42 Days

Heart rate

时间窗: 42 Days

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验